Immunotherapy of renal cell carcinoma: Results from current phase-III-trials;Immuntherapie des nierenzellkarzinoms: Ergebnisse aus aktuellen phase-III-studien

Aktuelle Urologie

Volumn 35, Issue 2, 2004, Pages 121-129

  Doehn, C ^a,b   Jocham, D ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Adjuvant; Autologous; Cytokine; Immunotherapy; Interferon; Interleukin; Metastasis; Phase III trial; Progression; Renal cell carcinoma; Survival; Vaccine

Indexed keywords

ALPHA2A INTERFERON; BEVACIZUMAB; FLUOROURACIL; GAMMA1B INTERFERON; INTERLEUKIN 2; RAPAMYCIN 2,2 BIS(HYDROXYMETHYL)PROPIONATE; TAMOXIFEN; VINBLASTINE;

CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE SEVERITY; HUMAN; KIDNEY CARCINOMA; METASTASIS; NEPHRECTOMY; PHASE 3 CLINICAL TRIAL; REVIEW;

ALGORITHMS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE III; COMBINED MODALITY THERAPY; CYTOKINES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FLUOROURACIL; HUMANS; IMMUNOTHERAPY; INTERFERON ALFA-2B; INTERFERON TYPE II; INTERLEUKIN-2; KIDNEY; KIDNEY NEOPLASMS; NEOPLASM STAGING; NEPHRECTOMY; TIME FACTORS;

EID: 2942607304     PISSN: 00017868     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-818414     Document Type: Review

References (23)

1. http://www.rki.de (aufgerufen 15. März 2004)
2. http://www.seer.cancer.gov (aufgerufen 15. März 2004)
3. Brenner H. Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis. Lancet 2002; 360: 1131-1135
4. Coppin C, Porzolt F, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2000; 3: CD001425
5. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20: 289-296
6. Pizzocaro G, Piva L, Colavita M, Ferri S, Artusi R, Boracchi P, Parmiani G, Marubini E. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 2001; 19: 425-431
7. Messing EM, Manola J, Wilding G, Propert K, Fleischmann J, Crawford ED, Pontes JE, Hahn R, Trump D, Eastern Cooperative Oncology Group/Intergroup trial. Phase III study of interferon-α-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 2003; 21: 1214-1222
8. Clark JI, Atkins MB, Urba WJ, Creech S, Figlin RA, Dutcher JP, Flaherty L, Sosman JA, Logan TF, White R, Weiss GR, Redman BG, Tretter CP, McDermott D, Smith JW, Gordon MS, Margolin KA. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 2003; 21: 3133-3140
9. Jocham D, Richter A, Hoffmann L, Iwig K, Fahlenkamp D, Zakrzewski G, Schmitt E, Dannenberg T, Lehmacher W, Wietersheim J von, Doehn C. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004; 363: 594-599
10. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton Jr JR, Munshi N, Crawford ED. Nephrectomy followed by interferon-α- 2b compared with interferon-α-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345: 1655-1659
11. Mickisch GH, Garin A, Poppel H van, de Prijck L, Sylvester R European Organisation for Research and Treatment of Cancer (EORTC) Genito-urinary Group. Radical nephrectomy plus interferon-α-based immunotherapy compared with interferon-α alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001; 358: 966-970
12. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Poppel H van, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004; 171: 1071-1076
13. Elhilali MM, Gleave M, Fradet Y, Davis I, Venner P, Saad F, Klotz L, Moore R, Ernst S, Paton V. Placebo-associated remissions in a multicentre, randomized, double-blind trial of interferon γ-1b for the treatment of metastatic renal cell carcinoma. The Canadian Urologic Oncology Group. BJU Int 2000; 86: 613-618
14. Gleave M, Elhilali MM, Fradet Y, Davis I, Venner P, Saad F, Klotz LH, Moore MJ, Paton V. Interferon γ-1b compared with placebo in metastatic renal-cell carcinoma. N Engl J Med 1998; 338: 1265-1271
15. Motzer RJ, Murphy BA, Bacik J, Schwartz LH, Nanus DM, Mariani T, Loehrer P, Wilding G, Fairclough DL, Cella D, Mazumdar M. Phase III trial of interferon-α-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000; 18: 2972-2980
16. Negrier S, Caty A, Lesimple T, Douillard J-Y, Escudier B, Rossi J-F, Viens P, Gomez F. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon-α with or without fluorouracil. J Clin Oncol 2000; 18: 4009-4015
17. Atzpodien J, Kirchner H, Illiger HJ, Metzner B, Ukena D, Schott H, Funke PJ, Gramatzki M, Jurgenson S, Wandert T, Patzelt T, Reitz M. IL-2 in combination with IFN- α and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer 2001; 85: 1130-1136
18. Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, Seipp CA, Rogers-Freezer L, Morton KE, White DE, Liewehr DJ, Merino MJ, Rosenberg SA. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003; 21: 3127-3132
19. Atzpodien J, Kirchner H, Jonas U, Bergmann L, Schott H, Heynemann H, Fornara P, Loening SA, Roigas J, Muller SC, Bodenstein H, Pomer S, Metzner B, Rebmann U, Oberneder R, Siebels M, Wandert T, Puchberger T, Reitz M. Interleukin-2- and Interferon Alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: A prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 2004; 22: 1188-1194
20. Huland E, Heinzer H, Timm S, Alamian M, Huland H. Immunotherapy of metastatic renal cell carcinoma in Germany. An assessment of the current status. Urologe A 2002; 41: 282-287
21. http://www.cancer.gov (aufgerufen 15. März 2004)
22. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-434
23. http://www.eortc.be (aufgerufen 15. März 2004)